What is a significant potential side effect of IV Ganciclovir in CMV treatment?

Bone marrow suppression is a notable side effect of IV Ganciclovir, particularly in the context of treating Cytomegalovirus (CMV) infections. This drug is an antiviral agent, and while it effectively inhibits viral replication, it can also have a profound impact on the bone marrow. This suppression can lead to a decrease in the production of blood cells, resulting in conditions such as leukopenia (reduction in white blood cells), thrombocytopenia (decreased platelets), and anemia (low red blood cell count). Such effects can increase the risk of infections, bleeding, and fatigue, making close monitoring essential during treatment.

The other options, while they may occur in some patients, are not as closely associated with the use of Ganciclovir specifically. For instance, headaches and nausea are common side effects of many medications but do not have the same level of clinical significance as bone marrow suppression in the context of Ganciclovir therapy. Increased appetite is generally not considered a side effect of this medication. Understanding the potential for bone marrow suppression helps in managing the overall care of patients receiving Ganciclovir and highlights the importance of regular blood monitoring during treatment.